经口机器人手术的临床价值:全国范围内开展前5年的结果
该回顾性分析基于美国国家癌症数据库(2010-2014年),比较经口机器人手术(TORS)、非机器人手术与经口激光显微手术(TLM)治疗临床T1-T2期口咽鳞状细胞癌(OPSCC)的肿瘤学结局与辅助治疗。共纳入TORS 2,224例、非机器人手术6,697例、TLM 333例。TORS与非机器人手术相比阳性切缘可能性更低(非机器人手术:HR 1.51,P<0.001),但与TLM无显著差异(HR 1.13,P=0.582)。TORS术后接受化放疗的可能性更低(TLM:HR 2.07,P<0.001;非机器人手术:HR 1.65,P<0.001),但单纯辅助放疗无显著差异。多因素Cox分析显示TORS与总生存期改善无显著关联(TLM:HR 1.31,P=0.233;非机器人手术:HR 1.12,P=0.303)。
要点
- TORS与非机器人手术相比阳性切缘可能性更低(HR 1.51,P<0.001),与TLM无显著差异(HR 1.13,P=0.582)。
- TORS术后接受化放疗的可能性低于TLM(HR 2.07,P<0.001)和非机器人手术(HR 1.65,P<0.001)。
- 多因素Cox分析中TORS与总生存期改善无显著关联(TLM:HR 1.31,P=0.233;非机器人手术:HR 1.12,P=0.303)。
核心结论
- TORS用于早期OPSCC的优势可能在于降低术后阳性切缘的可能性及后续辅助化放疗的需求。
研究设计与样本
- 回顾性分析美国国家癌症数据库(2010-2014年)中临床T1和T2期口咽鳞状细胞癌患者,比较TORS、非机器人手术与TLM。
- 共纳入TORS患者2,224例、非机器人手术患者6,697例、TLM患者333例。
- 采用卡方检验、Kaplan-Meier对数秩检验、Cox多因素分析、logistic回归及多项回归模型进行单因素和多因素生存分析。
主要发现
- 多数患者为白人男性,平均年龄约59岁。
- 各队列间肿瘤分期无显著差异,但TORS患者较非机器人手术和TLM患者更可能有N1至N3期淋巴结病变(69.8% vs. 62.0% vs. 59.7%,P<0.001)。
- TORS与非机器人手术相比阳性切缘可能性更低(非机器人手术:HR 1.51,P<0.001),与TLM相比无显著差异(TLM:HR 1.13,P=0.582)。
- TORS术后接受化放疗的可能性更低(TLM:HR 2.07,P<0.001;非机器人手术:HR 1.65,P<0.001),但单纯辅助放疗无显著差异(TLM:HR 1.06,P=0.569;非机器人手术:HR 0.96,P=0.655)。
- 多因素Cox分析显示TORS与总生存期改善无显著关联(TLM:HR 1.31,P=0.233;非机器人手术:HR 1.12,P=0.303)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To compare long-term oncologic outcomes and adjuvant therapies for patients treated with transoral robotic surgery (TORS), nonrobotic surgery, or transoral laser microsurgery (TLM). STUDY DESIGN: A retrospective analysis of the National Cancer Database (2010-2014). METHODS: Patients with clinical tumor (T)1 and T2 oropharyngeal squamous cell carcinomas (OPSCC) were classified into those receiving TORS versus nonrobotic surgery versus TLM. Univariate and multivariate survival analyses were conducted with chi-square tests; Kaplan-Meier log-rank test; and Cox multivariate, logistic regression, and multinomial regression modeling. RESULTS: We identified 2,224 OPSCC TORS patients; 6,697 nonrobotic surgery patients; and 333 TLM patients. The majority of patients were white males with a mean age of approximately 59 years. No significant difference was noted between the cohorts in tumor stage; however, TORS patients were more likely to have nodal (N)1 to N3 disease than nonrobotic surgery and TLM patients, respectively (69.8% vs. 62.0% vs. 59.7%, P < 0.001). TORS was associated with a lower likelihood of positive margins when compared to nonrobotic surgery, although not TLM (nonrobotic surgery: hazard ratio [HR] 1.51, P < 0.001, TLM: HR 1.13, P = 0.582). TORS was associated with lower likelihood of postsurgical chemoradiotherapy (TLM: HR 2.07, P < 0.001, nonrobotic surgery: 1.65, P < 0.001) but not adjuvant radiotherapy alone (TLM: HR 1.06, P = 0.569, nonrobotic surgery: 0.96, P = 0.655). On multivariate Cox analysis of overall survival, the use of TORS was not associated with increased survival (TLM: HR 1.31, P = 0.233, nonrobotic surgery: HR 1.12, P < 0.303). CONCLUSION: The advantages of TORS for early-stage OPSCC may be a lower likelihood of postsurgical positive margins and subsequent need for adjuvant chemoradiotherapy. LEVEL OF EVIDENCE: NA Laryngoscope, 129:1844-1855, 2019.
引用
- Li H, Torabi SJ, Park HS, et al. Clinical value of transoral robotic surgery: Nationwide results from the first 5 years of adoption. Laryngoscope. 2018. PMID: 30575965. doi:10.1002/lary.27740
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。